Related Experiment Video
Updated: Jun 10, 2026
Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
[Clinical implication of BRSK2 expression in pancreatic ductal adenocarcinoma]
Geng-ming Niu1, Yuan Ji, Da-yong Jin
1Pancreatic Cancer Group, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Objective:
To investigate the expression of BRSK2 (brain selective kinase 2) in pancreatic ductal adenocarcinoma and to understand its clinical implication.
Methods:
Resected tumor specimens of 79 pancreatic ductal adenocarcinoma were collected and paraffin-embedded for prepare. 0.5 microm sections. Immunohistochemical staining was employed to examine the expression pattern of BRSK2 translated protein. Semi-quantitative analysis was used to evaluate the intensity and content of protein expression in tumor tissues. The expression outcome was compared in peri-tumorous tissues and normal pancreatic tissues. Meanwhile, tumor samples were grouped according to their differentiation, TNM stage, with or without vascular or neural invasion. Then the possible relationship was explored between clinical, pathological and survival data and the expression profile of BRSK2 in tumor tissues.
Results:
BRSK2's expression was weak in normal pancreatic tissues, including islets and minor ducts such as intercalated ducts, intralobular ducts and interlobular ducts. BRSK2's expression was also weak in peri-tumorous tissues. BRSK2's expression was strong in pancreatic ductal adenocarcinomas. It had a close relationship with lymphatic metastasis, distant metastasis, TNM staging as well as peri-pancreatic neural invasion. Tumors with lymphatic metastasis, distant metastasis and peri-pancreatic neural invasion or at later stages showed a higher expression of BRSK2 than those without or those at early stages. However the expression had no correlation with tumor size, differentiation and vascular invasion. The expression of BRSK2 in pancreatic ductal adenocarcinomas was correlated with the prognosis of patients. Those with a higher expression pattern showed a shorter survival period.
Conclusion:
BRSK2 is up-regulated in pancreatic ductal adenocarcinoma. And its expression is correlated with tumor biological behaviors and patient prognosis.
Insights
Brain selective kinase 2 (BRSK2) is highly expressed in pancreatic cancer, correlating with advanced disease and poorer patient outcomes. This finding suggests BRSK2 may be a potential biomarker for pancreatic ductal adenocarcinoma progression.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis.
- Understanding the molecular mechanisms driving PDAC progression is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the expression levels of brain selective kinase 2 (BRSK2) in pancreatic ductal adenocarcinoma.
- To determine the clinical implications and prognostic value of BRSK2 expression in PDAC.
Main Methods:
- Immunohistochemical staining was performed on 79 resected pancreatic ductal adenocarcinoma specimens.
- Semi-quantitative analysis assessed BRSK2 protein expression intensity and levels.
- BRSK2 expression was correlated with clinicopathological features and patient survival data.
Main Results:
- BRSK2 expression was significantly upregulated in PDAC tissues compared to normal and peri-tumorous pancreatic tissues.
- Higher BRSK2 expression correlated with advanced TNM stage, lymphatic metastasis, distant metastasis, and perineural invasion.
- Elevated BRSK2 levels were associated with shorter patient survival, indicating a poor prognostic role.
Conclusions:
- BRSK2 is overexpressed in pancreatic ductal adenocarcinoma.
- BRSK2 expression serves as a potential biomarker for tumor aggressiveness and patient prognosis in PDAC.
